Dyne Therapeutics Inc (NASDAQ: DYN) is -47.37% lower on its value in year-to-date trading and has touched a low of $11.18 and a high of $47.45 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The DYN stock was last observed hovering at around $12.58 in the last trading session, with the day’s loss setting it -0.18%.
Currently trading at $12.40, the stock is -2.30% and -13.28% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.81 million and changing -1.43% at the moment leaves the stock -57.72% off its SMA200. DYN registered -55.70% loss for a year compared to 6-month loss of -63.95%. The firm has a 50-day simple moving average (SMA 50) of $14.2994 and a 200-day simple moving average (SMA200) of $29.32575.
The stock witnessed a -10.01% gain in the last 1 month and extending the period to 3 months gives it a -51.81%, and is 0.32% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.80% over the week and 6.34% over the month.
Dyne Therapeutics Inc (DYN) has around 191 employees, a market worth around $1.40B and $0.00M in sales. Distance from 52-week low is 10.91% and -73.87% from its 52-week high. The company has generated returns on investments over the last 12 months (-48.91%).
The EPS is expected to shrink by -4.89% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
277.0 institutions hold shares in Dyne Therapeutics Inc (DYN), with institutional investors hold 101.53% of the company’s shares. The shares outstanding are 102.32M, and float is at 84.07M with Short Float at 13.88%. Institutions hold 100.83% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 7.39 million shares valued at $$260.69 million. The investor’s holdings represent 9.1148 of the DYN Shares outstanding. As of 2024-06-30, the second largest holder is ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC with 8.02 million shares valued at $$283.03 million to account for 8.6697 of the shares outstanding. The other top investors are FCPM III SERVICES B.V. which holds 7.85 million shares representing 8.4808 and valued at over $$276.86 million, while RTW INVESTMENTS, LP holds 6.9044 of the shares totaling 6.39 million with a market value of $$225.4 million.
Dyne Therapeutics Inc (DYN) Insider Activity
The most recent transaction is an insider sale by Friedl-Naderer Johanna, the company’s Chief Commercial Officer. SEC filings show that Friedl-Naderer Johanna sold 143 shares of the company’s common stock on Mar 13 ’25 at a price of $12.12 per share for a total of $1733.0. Following the sale, the insider now owns 96057.0 shares.
Dyne Therapeutics Inc disclosed in a document filed with the SEC on Mar 11 ’25 that Scalzo Richard William (SVP, Head of Finance & Admin.) sold a total of 1,343 shares of the company’s common stock. The trade occurred on Mar 11 ’25 and was made at $11.38 per share for $15283.0. Following the transaction, the insider now directly holds 0.12 million shares of the DYN stock.
Still, SEC filings show that on Mar 11 ’25, Beskrovnaya Oxana (Chief Scientific Officer) disposed off 2,153 shares at an average price of $11.38 for $24501.0. The insider now directly holds 195,840 shares of Dyne Therapeutics Inc (DYN).
